Compare · MDLN vs TMCI
MDLN vs TMCI
Side-by-side comparison of Medline Inc. (MDLN) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 187.4x TMCI ($279.0M).
- Over the past year, MDLN is down 2.3% and TMCI is down 23.9% - MDLN leads by 21.5 points.
- MDLN has hit the wire 4 times in the past 4 weeks while TMCI has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- Medline Inc.
- Treace Medical Concepts Inc.
- Price
- -
- -
- Market cap
- $52.27B
- $279.0M
- 1M return
- +7.36%
- +4.48%
- 1Y return
- -2.33%
- -23.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 19
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest TMCI
- Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
- Sidoti Events, LLC's June Small-Cap Virtual Conference
- Amendment: Chief Executive Officer Treace John T. bought $99,196 worth of shares (24,606 units at $4.03), increasing direct ownership by 0.34% to 7,348,439 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $210,968 worth of shares (52,317 units at $4.03), increasing direct ownership by 0.71% to 7,376,150 units (SEC Form 4)
- Treace to Present at the Sidoti Small Cap Conference
- Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)
- Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)
- Director Bakewell John K was granted 30,000 shares, increasing direct ownership by 17% to 204,056 units (SEC Form 4)